These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 34238111)
1. Identification of imidazo[4,5-c]pyridin-2-one derivatives as novel Src family kinase inhibitors against glioblastoma. Zhang L; Yang Z; Sang H; Jiang Y; Zhou M; Huang C; Huang C; Wu X; Zhang T; Zhang X; Wan S; Zhang J J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1541-1552. PubMed ID: 34238111 [TBL] [Abstract][Full Text] [Related]
2. Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma. Musumeci F; Fallacara AL; Brullo C; Grossi G; Botta L; Calandro P; Chiariello M; Kissova M; Crespan E; Maga G; Schenone S Eur J Med Chem; 2017 Feb; 127():369-378. PubMed ID: 28076826 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of novel 1,3,4-thiadiazole derivatives as anti-glioblastoma agents targeting the AKT pathway. Szeliga M; Karpińska M; Rola R; Niewiadomy A Bioorg Chem; 2020 Dec; 105():104362. PubMed ID: 33074121 [TBL] [Abstract][Full Text] [Related]
5. A dual aurora and lim kinase inhibitor reduces glioblastoma proliferation and invasion. Rybin MJ; Laverde-Paz MJ; Suter RK; Affer M; Ayad NG; Feng Y; Zeier Z Bioorg Med Chem Lett; 2022 Apr; 61():128614. PubMed ID: 35151865 [TBL] [Abstract][Full Text] [Related]
6. Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines. Fallacara AL; Passannanti R; Mori M; Iovenitti G; Musumeci F; Greco C; Crespan E; Kissova M; Maga G; Tarantelli C; Spriano F; Gaudio E; Bertoni F; Botta M; Schenone S Eur J Med Chem; 2019 Nov; 181():111545. PubMed ID: 31400706 [TBL] [Abstract][Full Text] [Related]
7. Development of 2'-aminospiro [pyrano[3,2-c]quinoline]-3'-carbonitrile derivatives as non-ATP competitive Src kinase inhibitors that suppress breast cancer cell migration and proliferation. Ramadan M; A M M Elshaier Y; Aly AA; Abdel-Aziz M; Fathy HM; Brown AB; Pridgen JR; Dalby KN; Kaoud TS Bioorg Chem; 2021 Nov; 116():105344. PubMed ID: 34598088 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment. Cui Z; Li X; Li L; Zhang B; Gao C; Chen Y; Tan C; Liu H; Xie W; Yang T; Jiang Y Bioorg Med Chem; 2016 Jan; 24(2):261-9. PubMed ID: 26707846 [TBL] [Abstract][Full Text] [Related]
9. Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors. Francini CM; Fallacara AL; Artusi R; Mennuni L; Calgani A; Angelucci A; Schenone S; Botta M ChemMedChem; 2015 Dec; 10(12):2027-41. PubMed ID: 26514807 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment. Cui Z; Chen S; Wang Y; Gao C; Chen Y; Tan C; Jiang Y Eur J Med Chem; 2017 Aug; 136():372-381. PubMed ID: 28525838 [TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl)-1H-quinolin-2-ones as VEGFR-2 kinase inhibitors. Han SY; Choi JW; Yang J; Chae CH; Lee J; Jung H; Lee K; Ha JD; Kim HR; Cho SY Bioorg Med Chem Lett; 2012 Apr; 22(8):2837-42. PubMed ID: 22450128 [TBL] [Abstract][Full Text] [Related]
12. Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma. Nepali K; Hsu TI; Hsieh CM; Lo WL; Lai MJ; Hsu KC; Lin TE; Chuang JY; Liou JP Eur J Med Chem; 2021 May; 217():113338. PubMed ID: 33744690 [TBL] [Abstract][Full Text] [Related]
13. Proton Therapy and Src Family Kinase Inhibitor Combined Treatments on U87 Human Glioblastoma Multiforme Cell Line. Cammarata FP; Torrisi F; Forte GI; Minafra L; Bravatà V; Pisciotta P; Savoca G; Calvaruso M; Petringa G; Cirrone GAP; Fallacara AL; Maccari L; Botta M; Schenone S; Parenti R; Cuttone G; Russo G Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554327 [TBL] [Abstract][Full Text] [Related]
14. Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies. Ahluwalia MS; de Groot J; Liu WM; Gladson CL Cancer Lett; 2010 Dec; 298(2):139-49. PubMed ID: 20947248 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of c-Src kinase inhibitory activity of pyridin-2(1H)-one derivatives. Chand K; Prasad S; Tiwari RK; Shirazi AN; Kumar S; Parang K; Sharma SK Bioorg Chem; 2014 Apr; 53():75-82. PubMed ID: 24632506 [TBL] [Abstract][Full Text] [Related]
16. Src family kinases differentially influence glioma growth and motility. Lewis-Tuffin LJ; Feathers R; Hari P; Durand N; Li Z; Rodriguez FJ; Bakken K; Carlson B; Schroeder M; Sarkaria JN; Anastasiadis PZ Mol Oncol; 2015 Nov; 9(9):1783-98. PubMed ID: 26105207 [TBL] [Abstract][Full Text] [Related]
18. Synthesis, biological evaluation and docking studies of new pyrrolo[2,3-d] pyrimidine derivatives as Src family-selective tyrosine kinase inhibitors. Dincer S; Cetin KT; Onay-Besikci A; Ölgen S J Enzyme Inhib Med Chem; 2013 Oct; 28(5):1080-7. PubMed ID: 22957720 [TBL] [Abstract][Full Text] [Related]
19. 4-Aryl-4H-chromene-3-carbonitrile derivatives: evaluation of Src kinase inhibitory and anticancer activities. Fallah-Tafti A; Tiwari R; Shirazi AN; Akbarzadeh T; Mandal D; Shafiee A; Parang K; Foroumadi A Med Chem; 2011 Sep; 7(5):466-72. PubMed ID: 21801146 [TBL] [Abstract][Full Text] [Related]
20. Examination of sulfonamide-based inhibitors of MMP3 using the conditioned media of invasive glioma cells. Poole AT; Sitko CA; Le C; Naus CC; Hill BM; Bushnell EAC; Chen VC J Enzyme Inhib Med Chem; 2020 Dec; 35(1):672-681. PubMed ID: 32156166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]